Boundless Bio Inc (BOLD)

$1.20 +0.07 (6.19%)
Market Cap 25.32M
Revenue (ttm) 0.00
Net Income (ttm) -58.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 193,600
Avg Vol 111,740
Day's Range N/A - N/A
Shares Out 22.41M
Stochastic %K 81%
Beta -0.86
Analysts Hold
Price Target $4.00

Company Profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor s...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 766 9912
Address:
10955 Alexandria Way, Suite 100, San Diego, United States
AshToFlame
AshToFlame Apr. 14 at 12:21 AM
$BOLD
0 · Reply
AshToFlame
AshToFlame Apr. 13 at 11:16 PM
$BOLD on watch
0 · Reply
slacktime
slacktime Apr. 13 at 10:26 PM
$BOLD presenting on April 21st - Oral Kinesin Degrader Program- Late Breaking Research: Experimental and Molecular Therapeutics 3
0 · Reply
revuelto
revuelto Apr. 13 at 9:54 PM
$BOLD so is this where the climb begins? 🎉
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:30 PM
$BOLD IPO, public offering price of $16.00 per share, a substantial discount at the moment https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-announces-pricing-initial-public-offering?mobile=1
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:24 PM
$BOLD $BAYRY Bayer, not the least, not a small fry https://www.bayer.com/media/en-us/boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer/
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:18 PM
$BOLD If you buy this company, you will receive the following: cash, liquid assets, and short-term investments totaling $107.6 million; the market value is currently $27.45 million.
0 · Reply
revuelto
revuelto Apr. 8 at 11:25 PM
$BOLD potential for multi fold gains here, just requires patience…that’s the hardest part for most..
1 · Reply
NYBomba
NYBomba Apr. 6 at 5:07 PM
$BOLD - nice move today 👏👏👏 strong fundamentals so it can’t be an offering …. hoping the strong pipeline moves to next phase … ☮️
0 · Reply
slacktime
slacktime Apr. 6 at 4:22 PM
$BOLD small amount of shares moved this over 10%..get some vol and it should really move!
0 · Reply
Latest News on BOLD
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Mar 17, 2026, 4:52 PM EDT - 27 days ago

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Mar 9, 2026, 7:00 AM EDT - 5 weeks ago

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 5 weeks ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 7:00 AM EST - 2 months ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Jan 20, 2026, 7:00 AM EST - 2 months ago

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 5 months ago

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 5, 2025, 7:00 AM EST - 5 months ago

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 6 months ago

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 7:00 AM EDT - 8 months ago

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 4:58 PM EDT - 11 months ago

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Boundless Bio Announces Portfolio Prioritization and Runway Extension

May 23, 2025, 4:01 PM EDT - 11 months ago

Boundless Bio Announces Portfolio Prioritization and Runway Extension

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Apr 3, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Feb 26, 2025, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Feb 3, 2025, 10:00 AM EST - 1 year ago

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

Boundless Bio Announces Pipeline and Leadership Updates

Dec 12, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Announces Pipeline and Leadership Updates

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 7, 2024, 4:01 PM EST - 1 year ago

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 7:00 AM EDT - 1 year ago

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

May 13, 2024, 7:00 AM EDT - 2 years ago

Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024

Boundless Bio Announces Pricing of Initial Public Offering

Mar 27, 2024, 6:55 PM EDT - 2 years ago

Boundless Bio Announces Pricing of Initial Public Offering

AshToFlame
AshToFlame Apr. 14 at 12:21 AM
$BOLD
0 · Reply
AshToFlame
AshToFlame Apr. 13 at 11:16 PM
$BOLD on watch
0 · Reply
slacktime
slacktime Apr. 13 at 10:26 PM
$BOLD presenting on April 21st - Oral Kinesin Degrader Program- Late Breaking Research: Experimental and Molecular Therapeutics 3
0 · Reply
revuelto
revuelto Apr. 13 at 9:54 PM
$BOLD so is this where the climb begins? 🎉
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:30 PM
$BOLD IPO, public offering price of $16.00 per share, a substantial discount at the moment https://investors.boundlessbio.com/news-releases/news-release-details/boundless-bio-announces-pricing-initial-public-offering?mobile=1
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:24 PM
$BOLD $BAYRY Bayer, not the least, not a small fry https://www.bayer.com/media/en-us/boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer/
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:18 PM
$BOLD If you buy this company, you will receive the following: cash, liquid assets, and short-term investments totaling $107.6 million; the market value is currently $27.45 million.
0 · Reply
revuelto
revuelto Apr. 8 at 11:25 PM
$BOLD potential for multi fold gains here, just requires patience…that’s the hardest part for most..
1 · Reply
NYBomba
NYBomba Apr. 6 at 5:07 PM
$BOLD - nice move today 👏👏👏 strong fundamentals so it can’t be an offering …. hoping the strong pipeline moves to next phase … ☮️
0 · Reply
slacktime
slacktime Apr. 6 at 4:22 PM
$BOLD small amount of shares moved this over 10%..get some vol and it should really move!
0 · Reply
vu_jade
vu_jade Mar. 27 at 7:54 PM
$BOLD cash in the bank.. already down 99% from IPO… Let’s see what’s under their skirt!
0 · Reply
THSSKS
THSSKS Mar. 20 at 1:53 PM
$BOLD this could easily 2-3X from here.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 20 at 8:15 AM
$BOLD This one is trading under the radar. Just 700+watchers in stockwits. Just 66 folowers in SeekingAlpha. Not much discussion in X.
0 · Reply
Biotech_Pharma_Investor
Biotech_Pharma_Investor Mar. 20 at 8:14 AM
$BOLD My coverage for anyone interested. Trading at 1/4 of cash with a very promising first-in-class ecDNA-targeting kinesin degrader and a runway to 2H 2028 https://seekingalpha.com/article/4884418-boundless-bio-an-underestimated-biotech-with-a-first-in-class-ecdna-targeted-kinesin-degrader
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 19 at 2:35 AM
$BOLD RSI: 52.38, MACD: -0.0060 Vol: 0.02, MA20: 1.15, MA50: 1.18 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
revuelto
revuelto Mar. 18 at 8:07 PM
$BOLD initiated a position today ✌️
0 · Reply
Golibajje
Golibajje Mar. 14 at 1:54 AM
$BOLD One of the top among the worst biotech companies out there!! Surprised not a single lawsuit on them! Pipeline failure, no strategic direction.. hardly any progress.. yea!! milking the cash balance at ease!
1 · Reply
THSSKS
THSSKS Mar. 13 at 11:54 AM
$BOLD I’d like to see this liquidated or an activist pushing for strategic alternatives. Preferably Tang.
0 · Reply
vu_jade
vu_jade Mar. 9 at 6:12 PM
$BOLD $16 IPO lead by Goldman?
1 · Reply
TICKERTUTOR
TICKERTUTOR Mar. 5 at 3:21 PM
sold $ERAS and bought $BOLD
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:09 AM
$BOLD Current Stock Price: $1.16
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 3:52 AM
$BOLD RSI: 40.54, MACD: -0.0245 Vol: 0.06, MA20: 1.17, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply